TARDBP

TAR DNA-binding protein 43 · Q13148 · TARDBP on Sugi Atlas →

2,404 patent compounds predicted against TARDBP, 1,450 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Thioctic Acid (SCHEMBL7924)	1.00	2/20
Thioctic Acid Amide (SCHEMBL41833)	1.00	2/20
Thioctic Acid Amide (SCHEMBL50599)	1.00	2/20
Lipoic Acid, Alpha (SCHEMBL51065)	1.00	2/20
Lipoic Acid, Alpha (SCHEMBL1981737)	1.00	2/20
Lipoic Acid, Alpha (SCHEMBL2128472)	1.00	2/20
Thioctic Acid Amide (SCHEMBL4380181)	1.00	2/20
Thioctic Acid (SCHEMBL4611014)	1.00	2/20
Thioctic Acid (SCHEMBL4898896)	0.96	2/20
Lipoic Acid, Alpha (SCHEMBL4898905)	0.96	2/20
Thioctic Acid (SCHEMBL6037631)	0.96	2/20
Lipoic Acid, Alpha (SCHEMBL6037633)	0.96	2/20
SCHEMBL6809715	0.96	2/20
SCHEMBL6813513	0.96	2/20
SCHEMBL7914749	0.96	2/20
Thioctic Acid (SCHEMBL8948222)	0.96	2/20
SCHEMBL2058414	0.89	2/20
SCHEMBL7841850	0.89	2/20
Thioctic Acid Amide (SCHEMBL1895286)	0.87	2/20
Thioctic Acid Amide (SCHEMBL3400641)	0.87	2/20

Clinical trials — most relevant to TARDBP by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech	PHASE4	RECRUITING
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620	PHASE3	RECRUITING
Impact of the Combined Treatment of Liposomed Polyphenols With G04CB02 on the ALS Patients	PHASE2	COMPLETED
3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)	PHASE2	COMPLETED
Rho Kinase (ROCK) Inhibitor in Tauopathies - 1	PHASE2	UNKNOWN
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)	PHASE2	COMPLETED
Personalized Antisense Oligonucleotide Therapy for A Single Participant With TARDBP ALS	PHASE1/PHASE2	COMPLETED
Safety Study of TPI-287 to Treat CBS and PSP	PHASE1	COMPLETED
Trial of Oxaloacetate in ALS	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
[18F]ACI-19626 PET in TDP-43 Proteinopathies	EARLY_PHASE1	RECRUITING
Proteinopathies Expression in Skin of Neurodegenerative Disorders	nan	RECRUITING
Efficacy and Safety of Deep Cervical Lymph Node-vein Bypass Surgery in ALS Amyotrophic Lateral Sclerosis	nan	NOT_YET_RECRUITING
Predict to Prevent PGRN Disease	nan	WITHDRAWN
Translating Single-cell Vulnerability Into Novel ALS Biomarkers and Therapeutic Targets: Towards a Liquid Nerve Biopsy	nan	RECRUITING
Natural History Characterization in Symptomatic and Asymptomatic Progranuline Gene Mutation Carriers	nan	COMPLETED
Clinical Characteristics, Natural History, Health Care Measures, and Genetic Screening in Patients With ALS	nan	COMPLETED
Identification of New FTLD Genes	nan	UNKNOWN
In-depth Analysis of Cholesterol Metabolism and Related Biomarkers in the Pathogenesis and Progression of the Disease in Neurodegenerative Dementias	nan	RECRUITING
German Dementia Registry	nan	RECRUITING
Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches	nan	RECRUITING
Exposure to Neurotoxins as Risk Factors for ALS	nan	COMPLETED
Amyotrophic Lateral Sclerosis (ALS) Families Project	nan	RECRUITING
Neuroinflammation in FTLD	nan	ACTIVE_NOT_RECRUITING
Characterization of Platelet Molecular Profiles in ALS for the Identification of Specific Diagnostic Biomarkers - A Pilot Study	nan	NOT_YET_RECRUITING
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation	nan	COMPLETED
Genetics of Familial and Sporadic ALS	nan	COMPLETED
Digital Measurements of Motor and Voice Functions in FTD	nan	NOT_YET_RECRUITING
Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing	nan	RECRUITING
Epidemiological Study in FRONtoTemporal Dementia	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TARDBP binder may also engage these)

Protein	Name	Similarity
Q5R5W2	—	1.000	Q5R5W2 →
Q921F2	—	0.998	Q921F2 →
Q5ZLN5	—	0.998	Q5ZLN5 →
Q28F51	—	0.998	Q28F51 →
Q5NVC8	—	0.963	Q5NVC8 →
Q921F4	—	0.962	Q921F4 →
Q1RMJ7	—	0.961	Q1RMJ7 →
Q9Z1X4	—	0.961	Q9Z1X4 →
A0JMV4	—	0.960	A0JMV4 →
Q5R462	—	0.959	Q5R462 →
Q4R535	—	0.959	Q4R535 →
A4IGK4	—	0.959	A4IGK4 →
ILF3	Interleukin enhancer-binding factor 3	0.958	landscape →
Q9D0E1	—	0.958	Q9D0E1 →
Q7TSY6	—	0.958	Q7TSY6 →
Q9JIL3	—	0.958	Q9JIL3 →
Q7TN33	—	0.958	Q7TN33 →
Q9QZI7	—	0.958	Q9QZI7 →
HNRNPM	Heterogeneous nuclear ribonucleoprotein M	0.957	landscape →
Q9BZC1	—	0.956	Q9BZC1 →
Q6NXA4	—	0.956	Q6NXA4 →
Q8IUH3	—	0.956	Q8IUH3 →
Q8BHN5	—	0.955	Q8BHN5 →
Q8VC70	—	0.955	Q8VC70 →
YTHDF1	YTH domain-containing family protein 1	0.955	landscape →
Q8QFR2	—	0.955	Q8QFR2 →
SF3A1	Splicing factor 3A subunit 1	0.954	landscape →
O43815	—	0.954	O43815 →
Q6DDU9	—	0.954	Q6DDU9 →
HNRNPLL	Heterogeneous nuclear ribonucleoprotein L-like	0.954	landscape →